View all posters
2022 April 12 AACR Conference (poster 3599)

Interleukin-10 and transforming growth factor-b do not suppress tumor killing activity of PBMC-derived SUPLEXA cells

  1. The manufacture of SUPLEXA cells from PBMCs generates immune effector cell types with potent and broad tumor cell killing activity.
  2. Comprehensive phenotyping of SUPLEXA cells by CyTOF indicates that SUPLEXA cells are a mixture of NK cells, CD8+ T cells, CD56+ NK-like T cells, TCRγδ cells, and CD4 T cells that express high-levels of killer cell factors (granzymes and perforin) and activation markers (not shown).
  3. IL-10 significantly enhanced the killing activity and production of IFNγ, MIP-1α, and Rantes by SUPLEXA cells in a dose-dependent fashion.
  4. TGFβ1 modestly suppressed SUPLEXA cell mediated tumor cell killing activity and reduced IFNγ and MIP-1α production.
  5. SUPLEXA cells are entering Phase 1 clinical testing in Australia.
Download this poster